WO2009137632A3 - Immunogène du vih et son procédé de fabrication et d'utilisation - Google Patents

Immunogène du vih et son procédé de fabrication et d'utilisation Download PDF

Info

Publication number
WO2009137632A3
WO2009137632A3 PCT/US2009/043054 US2009043054W WO2009137632A3 WO 2009137632 A3 WO2009137632 A3 WO 2009137632A3 US 2009043054 W US2009043054 W US 2009043054W WO 2009137632 A3 WO2009137632 A3 WO 2009137632A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
making
same
antigen
hiv immunogen
Prior art date
Application number
PCT/US2009/043054
Other languages
English (en)
Other versions
WO2009137632A2 (fr
Inventor
Dimiter S. Dimitrov
Mei-Yun Zhang
Original Assignee
Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services filed Critical Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services
Publication of WO2009137632A2 publication Critical patent/WO2009137632A2/fr
Publication of WO2009137632A3 publication Critical patent/WO2009137632A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un antigène du VIH à base de gp41, comprenant un polypeptide gp41 ou un fragment immunogène de celui-ci, fusionné à un complexe ligand-récepteur Fc. Ledit antigène se révèle hautement immunogène, très stable et présente une bonne efficacité in vivo. Il est également à l'origine de la production d'anticorps neutralisants anti-VIH de réaction croisée et a pour intérêt de ne pas présenter les inconvénients des antigènes à base de gp41 déjà connus. L'invention concerne également des procédés de vaccination d'un sujet contre une infection par le VIH, procédés impliquant l'administration de l'antigène de l'invention ou d'une composition en contenant.
PCT/US2009/043054 2008-05-06 2009-05-06 Immunogène du vih et son procédé de fabrication et d'utilisation WO2009137632A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12666208P 2008-05-06 2008-05-06
US61/126,662 2008-05-06

Publications (2)

Publication Number Publication Date
WO2009137632A2 WO2009137632A2 (fr) 2009-11-12
WO2009137632A3 true WO2009137632A3 (fr) 2010-02-25

Family

ID=41265392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/043054 WO2009137632A2 (fr) 2008-05-06 2009-05-06 Immunogène du vih et son procédé de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2009137632A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015106003A1 (fr) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Voies de ras en tant que marqueurs de protection contre le vih et méthode d'amélioration d'efficacité de vaccin
CN107383190B (zh) * 2017-08-03 2020-09-25 深圳市慢性病防治中心 人源抗HIV gp41特异性抗体及其应用
UY37975A (es) * 2017-11-17 2019-02-28 Grifols Diagnostic Solutions Inc Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214285A1 (en) * 2003-02-10 2004-10-28 Glass David J. HIV-specific fusion proteins and therapeutic and diagnostic methods for use
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014148A1 (en) * 2002-07-23 2006-01-19 Barton Haynes Igg fc/hiv-gp120/c3d fusion protien
US20040214285A1 (en) * 2003-02-10 2004-10-28 Glass David J. HIV-specific fusion proteins and therapeutic and diagnostic methods for use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LUO, M. ET AL.: "Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) pl5E fragment", VACCINE, vol. 24, no. 4, 23 January 2006 (2006-01-23), pages 435 - 442 *
MANTIS N. J. ET AL.: "Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies", VACCINE, vol. 19, no. 28-29, 16 July 2001 (2001-07-16), pages 3990 - 4001 *
YE, L. ET AL.: "Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein", VIROLOGY, vol. 352, no. 1, 15 August 2006 (2006-08-15), pages 74 - 85 *
ZHANG, M.-Y. ET AL.: "Cross-reactive HIV-l-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen", VACCINE, vol. 27, no. 6, 5 February 2009 (2009-02-05), pages 857 - 863 *

Also Published As

Publication number Publication date
WO2009137632A2 (fr) 2009-11-12

Similar Documents

Publication Publication Date Title
TWI659968B (zh) 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CY1110157T1 (el) Χιμαιρικα ανασυνδυασμενα αντιγονα του toxoplasma gondii
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2015012904A3 (fr) Immunoconjugués anticorps-sn-38 avec un lieur cl2a
WO2006036550A3 (fr) Vaccins a base de llo et de listeria
SG10201809694PA (en) Antibody neutralizing human respiratory syncytial virus
WO2010010466A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
WO2011000962A9 (fr) Nouveaux agents thérapeutiques et de diagnostic
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
PE20120539A1 (es) Anticuerpos anti-her biespecifico
WO2007022151A3 (fr) Immunisation d'oiseaux par administration de vaccins a vecteurs non repliquants
BRPI0412245A (pt) anticorpos de rg1 e usos destes
WO2009154995A3 (fr) Anticorps du récepteur de l'interleukine 10 (il-10r) et méthodes d'utilisation
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
WO2010132561A3 (fr) Nouvelles souches de rotavirus humain et nouveaux vaccins
WO2016130560A3 (fr) Déterminants antigéniques des lymphocytes t à réactivité croisée du vih, du vis et du vif pour vaccins pour l'être humain et le chat
WO2013076702A3 (fr) Anticorps monoclonaux spécifiques à l'antigène m2-1 du virus respiratoire syncytial (vrs)
EA200970731A1 (ru) Рекомбинантные антигены цитомегаловируса человека (hcmv)
WO2008118487A3 (fr) Compositions et procédés pour augmenter l'immunogénicité de vaccins à base de glycoprotéine
WO2009137632A3 (fr) Immunogène du vih et son procédé de fabrication et d'utilisation
WO2018066999A3 (fr) Particules pseudo-virale d'entérovirus chimériques
WO2009042538A3 (fr) Protéines immunogènes provenant d'une membrane extérieure dérivée du génome de leptospira et compositions et procédés à base de celles-ci
WO2006091455A3 (fr) Echafaudages moleculaires destines a des immunogenes hiv-1
WO2007052238A8 (fr) Antigenes chimeriques et vaccins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743618

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09743618

Country of ref document: EP

Kind code of ref document: A2